Journal Home
Search for

Volume 180, Issue 5, Pages 2262-2263 (November 2008)


View previous. 134 of 139 View next.

Errata

published online 22 September 2008.

Refers to article:
Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis , 18 February 2008
J. Stuart Wolf, Carol J. Bennett, Roger R. Dmochowski, Brent K. Hollenbeck, Margaret S. Pearle, Anthony J. Schaeffer
The Journal of Urology
April 2008 (Vol. 179, Issue 4, Pages 1379-1390)
Abstract | Full Text | Full-Text PDF (165 KB)

Article Outline

Best Practice Policy Statement on Antimicrobial Prophylaxis

Copyright

Best Practice Policy Statement on Antimicrobial Prophylaxis 

return to Article Outline

Volume 179, Number 4, Pages 1383 and 1384, Table 3a, Table 3b (in bold): Second/third cephalosporins have been added as one of the “Antimicrobial(s) of Choice” for transrectal prostate biopsy. This addition provides a non-nephrotoxic alternative to fluoroquinolones for use when fluoroquinolone resistance is elevated. Aztreonam has been added as an alternative to aminoglycosides in cases of renal insufficiency. Clarification has been provided that oral agents can be used for prophylaxis for transrectal prostate biopsy and that vaginal surgery includes urethral sling procedures.

Table 3a.

Recommended antimicrobial prophylaxis for urologic procedures

Procedure
Organisms
Prophylaxis Indicated
Antimicrobial(s) of Choice
Alternative Antimicrobial(s)
Duration of Therapy
Lower Tract Instrumentation
Removal of external urinary catheterGU tractIf risk factors,§

- Fluoroquinolone

- TMP-SMX


- Aminoglycoside (Aztreonam¥) ± Ampicillin

- 1st/2nd gen. Cephalosporin

- Amoxacillin/Clavulanate

≤24 hours
Cystography, urodynamic study, or simple cystourethroscopyGU tractIf risk factors§

- Fluoroquinolone

- TMP-SMX


- Aminoglycoside (Aztreonam¥) ± Ampicillin

- 1st/2nd gen. Cephalosporin

- Amoxacillin/Clavulanate

≤24 hours
Cystourethroscopy with manipulationGU tractAll

- Fluoroquinolone

- TMP-SMX


- Aminoglycoside (Aztreonam¥) ± Ampicillin

- 1st/2nd gen. Cephalosporin

- Amoxacillin/Clavulanate

≤24 hours
Prostate brachytherapy or cryotherapySkinUncertain- 1st gen. Cephalosporin- Clindamycin⁎⁎≤24 hours
Transrectal prostate biopsyIntestine††All

- Fluoroquinolone

- 2nd/3rd gen. Cephalosporin

- Aminoglycoside (Aztreonam¥) + Metronidazole or Clindamycin⁎⁎≤24 hours
Upper Tract Instrumentation
Shock-wave lithotripsyGU tractAll

- Fluoroquinolone

- TMP-SMX


- Aminoglycoside (Aztreonam¥) ± Ampicillin

- 1st/2nd gen. Cephalosporin

- Amoxacillin/Clavulanate

≤24 hours
Percutaneous renal surgeryGU tract and skin‡‡All

- 1st/2nd gen. Cephalosporin

- Aminoglycoside (Aztreonam¥) + Metronidazole or Clindamycin


- Ampicillin/Sulbactam

- Fluoroquinolone

≤24 hours
UreteroscopyGU TractAll

- Fluoroquinolone

- TMP-SMX


- Aminoglycoside (Aztreonam¥) ± Ampicillin

- 1st/2nd gen. Cephalosporin

- Amoxacillin/Clavulanate

≤24 hours
Open or Laparoscopic Surgery
Vaginal surgery (includes urethral sling procedures)GU tract, skin and Grp B Strep.All

- 1st/2nd gen. Cephalosporin

- Aminoglycoside (Aztreonam¥) + Metronidazole or Clindamycin


- Ampicillin/Sulbactam

- Fluoroquinolone

≤24 hours
Without entering urinary tractSkinIf risk factors- 1st gen. Cephalosporin- ClindamycinSingle dose
Involving entry into urinary tractGU tract and skinAll

- 1st/2nd gen. Cephalosporin

- Aminoglycoside (Aztreonam¥) + Metronidazole or Clindamycin


- Ampicillin/Sulbactam

- Fluoroquinolone

≤24 hours
Involving intestine§§GU tract, skin and intestineAll

- 2nd/3rd gen. Cephalosporin

- Aminoglycoside (Aztreonam¥) + Metronidazole or Clindamycin


- Ampicillin/Sulbactam

- Ticarcillin/Clavulanate

- Pipercillin/Tazobactam

- Fluoroquinolone

≤24 hours
Involving implanted prosthesisGU tract and skinAll- Aminoglycoside (Aztreonam¥) + 1st/2nd gen. Cephalosporin or Vancomycin

- Ampicillin/Sulbactam

- Ticarcillin/Clavulanate

- Pipercillin/Tazobactam

≤24 hours

Order of agents in each column is not indicative of preference. The absence of an agent does not preclude its appropriate use depending on specific situations.

Key

Key: gen, generation; GU, genitourinary; TMP-SMX, trimethoprim-sulfamethoxazole.

Additional antimicrobial therapy may be recommended at the time of removal of an externalized urinary catheter.

GU tract: Common urinary tract organisms are E. coli, Proteus sp., Klebsiella sp., Enterococcus.

See Table 1 “Patient-related factors affecting host response to surgical infections.”

§

If urine culture shows no growth prior to the procedure, antimicrobial prophylaxis is not necessary.

Or full course of culture-directed antimicrobials for documented infection (which is treatment, not prophylaxis).

¥

Aztreonam can be substituted for aminoglycosides in patients with renal insufficiency.

Includes transurethral resection of bladder tumor and prostate, and any biopsy, resection, fulguration, foreign body removal, urethral dilation or urethrotomy, or ureteral instrumentation including catheterization or stent placement/removal.

⁎⁎

Clindamycin, or aminoglycoside + metronidazole or clindamycin, are general alternatives to penicillins and cephalosporins in patients with penicillin allergy, even when not specifically listed.

††

Intestine: Common intestinal organisms are E. coli, Klebsiella sp., Enterobacter, Serratia sp, Serratia sp., Proteus sp., Enterococcus, and Anaerobes.

‡‡

Skin: Common skin organisms are S. aureus, coagulase negative Staph. sp., Group A Strep. sp.

§§

For surgery involving the colon, bowel preparation with oral neomycin plus either erythromycin base or metronidazole can be added to or substituted for systemic agents.

Table 3b.

Antimicrobial agents and doses for periprocedure use


For surgical prophylaxis, all agents should be administered IV except fluoroquinolones, trimethoprim-sulfamethoxazole, oral agents for bowel preparation, and some agents given at catheter removal or transrectal prostate biopsy.

Dosages may vary with specific patient and situation.

For prolonged procedures, repeat intraoperative dosing may be indicated sooner than the intervals indicated in the Table.

Level-based dosing can be used for several agents, but is not applicable to periprocedural use less than or equal to 24 hours, and as such are not included in the Table.

Drug classification lists are not all-inclusive.

Fluoroquinolones

Levafloxacin: 500 mg PO single dose

Ciprofloxacin: 500 mg PO [q12h]

Ofloxacin: 400 mg PO [q12h]

Aminoglycosides

Gentamicin: 5 mg/kg IV single dose

Tobramycin: 5 mg/kg IV single dose

Amikacin: 15 mg/kg IV single dose

1st Generation cephalosporins

Cephalexin: 500 mg PO [q6h]

Cephradine: 500 mg PO [q6h]

Cefadroxil: 500 mg PO [q12h]

Cefazolin: 1 g IV [q8h]

2nd Generation cephalosporins

Cefaclor: 500 mg PO [q8h]

Cefprozil: 500 mg PO [q12h]

Cefuroxime: 500 mg PO [q12h]

Cefoxitin: 1–2 g IV [q8h]

3rd Generation cephalosporins (oral agents not listed)

Ceftizoxime: 1 g IV [q8h]

Ceftazidime: 1 g IV [q12h]

Ceftriaxone: 1–2 IV single dose

Cefotaxime: 1 g IV [q8h]

Others

Amoxicillin/clavulanate: 875 mg PO [q12h]

Ampicillin: 1–2 g IV [q6h]

Ampicillin/sulbactam: 1.5–3 g IV [q6h]

Aztreonam: 1–2 g IV [q8h]

Clindamycin: 600 mg IV [q8h]

Erythromycin base (for bowel preparation): 1–2 g PO [variable]

Metronidazole: 1 g IV [q12h]; (for bowel preparation) 1–2 g PO [variable]

Neomycin (for bowel preparation): 1–2 g PO [variable]

Pipercillin/tazobactam: 3.375 g IV [q6h]

Ticarcillin/clavulanate: 3.1 g IV [q6h]

Trimethoprim-sulfamethoxazole: 1 double-strength tablet PO [q12h]

Vancomycin: 1 g IV [q12h]

Key: g, gram; h, hour; IV, intravenous; kg, kilogram; mg, milligram; PO, orally; q, every.

PII: S0022-5347(08)02505-6

doi:10.1016/j.juro.2008.09.059


View previous. 134 of 139 View next.